Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: December 2022

MissionIRNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) at Forefront to Supply North American Grid with Clean Energy

Posted on December 29, 2022 by MissionIR

EverGen (TSX.V: EVGN) (OTCQX: EVGIF) ranks amongst the leaders in driving the ongoing shift towards renewable energy resources within Canada, having firmly established itself as one of the leading renewable natural gas (“RNG”) infrastructure platforms in the country. “EverGen has … Continue reading →

Posted in EverGen Infrastructure Corp. EVGIF | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market

Posted on December 29, 2022 by MissionIR

BiondVax (NASDAQ: BVXV) is focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is developing a pipeline of nanosized antibody (‘NanoAb’) therapies addressing diseases underserved by current treatments and with … Continue reading →

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures 28th Patent in International Portfolio

Posted on December 29, 2022 by MissionIR

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its continued accumulation of international patent recognition with the receipt of its first granted patent in Canada, which is its 28th granted patent worldwide. According to … Continue reading →

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Shareholder Letter, Including Corporate Update

Posted on December 29, 2022 by MissionIR

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has issued a letter to shareholders. The letter, signed by HeartBeam CEO and founder Branislav Vajdic … Continue reading →

Posted in HeartBeam Inc. BEAT | Leave a comment

MissionIRNewsBreaks – Tingo Inc. (TMNA) Partners with Dozy Mmobousi to Open Leadership Centre

Posted on December 29, 2022 by MissionIR

Tingo (OTC: TMNA), a leading agrifintech business in Africa, and Dozy Mmobuosi, renowned technology entrepreneur and philanthropist, have together unveiled the Dozy Mmobuosi Leadership Centre (DMLC), located in Oxford, United Kingdom. The centre is designed to offer a monthlong, in-person transformational … Continue reading →

Posted in Tingo Inc. TMNA | Leave a comment

MissionIRNewsBreaks – Eloro Resources Ltd.’s (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Investment Appeal Bolstered by Iska Iska Mine’s Potential, Strong Technical Expertise

Posted on December 28, 2022 by MissionIR

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) has emerged as one of the most promising mining companies in the Americas, boasting access to one of the largest, undeveloped mining tracts within Bolivia’s Potosi region. “Having signed a definitive option … Continue reading →

Posted in Eloro Resources Ltd. ELRRF, MissionIRNewsBreaks | Leave a comment

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

Posted on December 28, 2022 by MissionIR

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. These technologies … Continue reading →

Posted in Aditxt Inc. ADTX | Leave a comment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial

Posted on December 28, 2022 by MissionIR

A Phase 2, globally sited clinical trial evaluating the potential efficacy of a promising brain cancer drug candidate against deadly glioblastoma (“GBM”) tumors is proceeding apace with a variety of patient profiles, affirming the drug developer’s confidence in its product.  … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

M&A Activity Keeps Flora Growth Corp. (NASDAQ: FLGC) Revenues Strong Amid Expected Rebound in Cannabis Industry

Posted on December 28, 2022 by MissionIR

In spite of outside pressures on the cannabis sector, some analysts are predicting a reversal in the trend during the coming months (https://ibn.fm/NDYRj), and the most resourceful companies are continuing to build income channels amid the slowdown. International cannabis cultivator, … Continue reading →

Posted in Flora Growth Corp. FLGC | Leave a comment

MissionIRNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes on Acquisition of Multinational Medical Cannabis Operator

Posted on December 27, 2022 by MissionIR

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has completed a “plan of arrangement,” or acquisition, of Franchise Global Health Inc. (TSX.V: FGH), a multinational operator in the medical cannabis and pharmaceutical … Continue reading →

Posted in Flora Growth Corp. FLGC | Leave a comment